BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19717382)

  • 1. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
    Berenson JR; Yellin O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal gammopathy of undetermined significance].
    Chaïbi P; Merlin L; Thomas C; Piette F
    Ann Med Interne (Paris); 2002 Nov; 153(7):459-66. PubMed ID: 12598832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA; Rajkumar SV
    Br J Haematol; 2007 Dec; 139(5):730-43. PubMed ID: 18021088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A; Czarkowska-Paczek B
    Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benign monoclonal gammopathy].
    Shirota T; Kondo M; Uchida H; Ito H
    Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal gammopathy of undetermined significance: a consensus statement.
    Berenson JR; Anderson KC; Audell RA; Boccia RV; Coleman M; Dimopoulos MA; Drake MT; Fonseca R; Harousseau JL; Joshua D; Lonial S; Niesvizky R; Palumbo A; Roodman GD; San-Miguel JF; Singhal S; Weber DM; Zangari M; Wirtschafter E; Yellin O; Kyle RA
    Br J Haematol; 2010 Jul; 150(1):28-38. PubMed ID: 20507313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
    Madan S; Greipp PR
    Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; Rajkumar SV
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathies of undetermined significance.
    Kyle RA; Rajkumar SV
    Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
    Guerard EJ; Tuchman SA
    Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal gammopathy of undetermined significance: a new proposal of workup.
    Mangiacavalli S; Cocito F; Pochintesta L; Pascutto C; Ferretti V; Varettoni M; Zappasodi P; Pompa A; Landini B; Cazzola M; Corso A
    Eur J Haematol; 2013 Oct; 91(4):356-60. PubMed ID: 23859528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal gammopathy of undeterminated significance: introduction and current clinical issues.
    Klincová M; Sandecká V; Mikuláiová A; Radocha J; Maisnar V; Hájek R
    Klin Onkol; 2011; 24 Suppl():S14-7. PubMed ID: 21923058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurologic sequelae of bone changes in multiple myeloma and its therapy].
    Basić-kes V; Basić-Jukić N; Kes P; Demarin V; Labar B
    Acta Med Croatica; 2002; 56(3):103-7. PubMed ID: 12630341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic criteria of multiple myeloma.
    Kyle RA
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):347-58. PubMed ID: 1582977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
    Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
    Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
    Jimenez-Zepeda VH; Heilman RL; Engel RA; Carey EJ; Freeman C; Rakela J; Mulligan DC; Fonseca R; Stewart AK
    Transplantation; 2011 Sep; 92(5):570-4. PubMed ID: 21712755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: clinical features and indications for therapy.
    Dispenzieri A; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.